Promoting lymphocyte infiltration in tumors by other approaches, such as by targeted delivery of LIGHT (TNFSF14) gene to the tumor [101] or by targeted type I IFN activation through peritumoral injections of immunostimulatory RNA (poly:IC) [102], has also been shown to overcome resistance to anti–PD-1 and/or anti–PD-L1 therapies, demonstrating that the presence of lymphocytes at cancer sites is the basis for effective immunotherapy with ICIs. The gene discussed is TNFSF14; the disease is neoplasm.